Latest Articles and Analysis

European price controls demonstrate MFN policy risks: delayed access, treatment rationing, and pharmaceutical innovation collapse.

September government shutdown threatens healthcare systems during November open enrollment, risking coverage loss for 22 million Americans.

Congressional Budget Office confirms 340B program expansion driven by hospital exploitation rather than pharmaceutical price inflation.

RFK Jr's dismantling of CDC scientific leadership replaces expertise with anti-vaccine ideology and predetermined policy conclusions.

Trump administration's revocation of competition executive order accelerates healthcare consolidation and threatens patient access.

Most Favored Nation pricing threatens to import restrictive QALY-based frameworks that discriminate against expensive treatments.

HRSA clarifies 340B eligibility for STI clinics while manufacturers challenge Ryan White program participation.

HRSA's 340B pilot program replicates existing successful models rather than addressing structural program exploitation.

Q3 2025 Watch: critical analysis including Cure Hepatitis C Act proposing subscription treatment models.

Expiration of enhanced ACA subsidies threatens to increase premiums 75% and reduce marketplace enrollment by millions.

340B program expansion drains billions from state Medicaid budgets while failing to deliver promised drug cost savings.

RFK Jr's Administration for a Healthy America proposes to dismantle infectious disease capacity while emphasizing unproven chronic disease theories.

Caregiving infrastructure supports health equity and healthcare outcomes, requiring policy investment in caregiving infrastructure.

CMS draft guidance on 340B claims modifiers creates ambiguity and enforcement gaps threatening program integrity and beneficiary access.

Antibiotic-resistant bacteria threaten basic medical procedures while drug development incentives prove inadequate for innovation.

Pharmacy benefit managers extract billions while adding no value, increasing costs without improving patient access or health outcomes.

Trump administration's contradictory drug pricing policies undermine goals of affordability and innovation incentives.

Federal spending cuts disproportionately impact vulnerable populations relying on safety-net programs and community health services.

State Prescription Drug Affordability Boards limit public input while basing pricing decisions on flawed methodologies.

Deteriorating public health surveillance capacity creates blind spots for emerging disease threats and health disparities.